Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?

Answer from: Radiation Oncologist at Academic Institution

No. Osimertinib alone is a palliative treatment with limited durability, which is not appropriate as first-line therapy for a patient who is interested in and eligible for definitive treatment. While the outcomes of the control arm of chemoradiotherapy without osimertinib in the LAURA trial were cer...

Comments

Medical Oncologist at Henry Ford Cancer Institute/Henry Ford Hospital
Agree. However, the question is whether starting w...

Radiation Oncologist at Yale School of Medicine
Interesting study idea! I would worry a bit about ...

Radiation Oncologist at Wake Forest School of Medicine
Smith et al., PMID 36923158 Concurrent osim...

Medical Oncologist at Kaiser Permanente
I want to add my 2 cents and the reason for my que...

Medical Oncologist at Los Angeles VA Medical Center
Dr. @Chunhui Fang, you can consider Dr. @Tejas Pat...

Answer from: Radiation Oncologist at Community Practice

I would not. The results generated in the winning arm of the LAURA trial were not achieved with osimertinib alone. It was achieved with CRT followed by osimertinib.

Please select the option that best describes you:

Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?

Related Questions